| Epoprostenol | heart failure, in all type of patient | vs standard care | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiac death | no data | | All cause death | 1.29 [0.90 1.87] | p=1.00 | 0 | 471 | 1 | FIRST, |
| Trial | Studied treatment | Control | Patients |
|---|
| FIRST, 1997 | epoprostenol infusion | standard care | Patients with class IIIB/IV congestive
heart failure and decreased left ventricular ejection fraction |
| |
| Nesiritide | heart failure, in acute decompensated heart failure | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| NSGET (comparative trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | usual care | acutely decompensated heart failure requiring invasive monitoring
|
| |
| Nesiritide | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | 1.11 [1.00 1.23] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | 30-day death | 0.90 [0.70 1.15] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | Death from any cause or hospitalization for heart failure | 0.93 [0.80 1.10] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | hospitalisation for heart failure | 0.98 [0.81 1.20] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | All cause death | 0.93 [0.73 1.18] | p=1.00 | 0 | 7371 | 3 | NSGET (efficacy trial), PROACTION, ASCEND-HF, |
| Trial | Studied treatment | Control | Patients |
|---|
| NSGET (efficacy trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | placebo | acutely decompensated heart failure requiring invasive monitoring | | PROACTION, 2003 | nesiritidefor at least 12h | placebo | patients presenting to the ED with acutely decompensated
HF and dyspnea at rest or with minimal activity | | BNP-CARDS, 2007 | nesiritide as a 0.01-µg/kg/min infusion for 48 hours | placebo | acute decompensated heart failure with moderate to severe renal insufficiency | | ASCEND-HF, 2011 | intravenous nesiritide for 24 hours to 7 days on top of standard therapy | matching placebo | Patients hospitalized for heart
failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF) | | VMAC (intravenous neseritide), 2002 | intravenous nesiritidefor 3 hours | placebo | acutely decompensated heart failure requiring hospitalization |
| |
| Nesiritide | | vs dobutamine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PRECEDENT, 2002 | nesiritide(0.015 or 0.03 microg/kg/min) | Dobutamine (> or =5 microg/kg/min) | Symptomatic, Decompensated CHF |
| |
| Nesiritide | | vs nitroglycerin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | 1.56 [0.76 3.19] | p=1.00 | 0 | 498 | 1 | VMAC (24h), |
| Trial | Studied treatment | Control | Patients |
|---|
| VMAC (24h), 2002 | nesiritideinfusion for 24 hours | nitroglycerin | acutely decompensated heart failure requiring hospitalization |
| |
| Nesiritide | | vs standard care | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FUSION 1, 2004 | nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly | standard care | outpatient with co-morbid advanced heart failure and renal insufficiency |
| |
| Nesiritide | heart failure, in all type of patient | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FUSION 2, 2008 | nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours) | placebo | patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min |
| |
| Nesiritide | | vs standard care | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FUSION 1, 2004 | nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly | standard care | outpatient with co-morbid advanced heart failure and renal insufficiency |
| |
| Hydralazine | heart failure, in all type of patient | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiac death | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Chatterjee, 1980 | oral hydralazine | NA | patients with chronic CHF |
| |
| Hydralazine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiac death | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Franciosa, 1982 | hydralazine 200 mg daily | placebo | patients with class III and IV symptoms while they were taking digitalis and diuretics | | Conradson , 1984 | hydralazine | placebo | patients with chronic congestive heart failure (NYHA class III) | | Magorien , 1984 | hydralazine 100 mg orally every eight hours | placebo | patients with idiopathic dilated cardiomyopathy |
| |
| Hydralazine-ISDN | heart failure, in all type of patient | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiac death | no data | | All cause death | 0.88 [0.60 1.29] | p=1.00 | 0 | 459 | 1 | VHeFT I (hydralazine ISDN), |
| Trial | Studied treatment | Control | Patients |
|---|
| VHeFT I (hydralazine ISDN), 1986 | hydralazine 300mg/d ISDN 160mg/d | placebo | patienst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance |
| |
| Isosorbide dinitrate | heart failure, in all type of patient | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiac death | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| NICE (Lewis), 1999 | isosorbide-5-mononitrate 50 mg once daily | placebo | patients (NYHA Class 2-3) treated for heart failure, all receiving captopril and most also furosemide | | Franciosa , 1978 | isosorbide dinitrate | placebo | |
| |
| Buflomedil | peripheral vascular diseases, in all type of patients | vs placebo | cardiovascular events by 26% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.74 [0.56 0.98] | p=0.04 | 0 | 2078 | 1 | LIMB, | | Cardiovascular death | 0.76 [0.48 1.18] | p=1.00 | 0 | 2078 | 1 | LIMB, | | myocardial infarction (fatal and non fatal) | 0.90 [0.39 2.09] | p=1.00 | 0 | 2118 | 2 | LIMB, Diamantopoulos, | | stroke (fatal and non fatal) | 1.17 [0.52 2.63] | p=1.00 | 0 | 2078 | 1 | LIMB, | | Revascularization | no data | | All cause death | 0.88 [0.63 1.23] | p=1.00 | 0 | 2118 | 2 | LIMB, Diamantopoulos, | | Treatment related complication | 0.93 [0.76 1.15] | p=1.00 | 0 | 2078 | 1 | LIMB, |
| Trial | Studied treatment | Control | Patients |
|---|
| LIMB, 2008 | buflomedil 150-300 mg twice daily adjusted to creatinine clearance | placebo | Patients >40 years with documented peripheral arterial obstructive disease, intermittent claudication, and an ankle-brachial index between 0.30 and 0.80 | | Diamantopoulos, 2001 | Buflomedil 600 mg/ d | placebo | Stade de la maladie: II de 3.4 ans en moyenne. |
| |
| Cilostazol | peripheral vascular diseases, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.13 [0.28 4.57] | p=1.00 | 0 | 597 | 2 | Beebe, Dawson, | | stroke (fatal and non fatal) | 1.23 [0.24 6.40] | p=1.00 | 0 | 516 | 1 | Beebe, | | Revascularization | 0.69 [0.22 2.20] | p=1.00 | 0 | 516 | 1 | Beebe, | | All cause death | 0.95 [0.31 2.88] | p=1.00 | 0 | 1696 | 5 | Beebe, Dawson, Money, Strandness, Dawson (cilostazol), | | Treatment related complication | 1.50 [0.89 2.52] | p=1.00 | 0 | 633 | 2 | Money, Strandness, |
| Trial | Studied treatment | Control | Patients |
|---|
| Beebe, 1999 | Cilostazol 100 ou 200 mg / j (2 groupes) | placebo | AOMI stade II | | Dawson, 1998 | Cilostazol 200 mg/d | placebo | Stade de la maladie: II, avec durée des symptomes (années) de : 6.25+/-0.82 | | Money, 1998 | Cilostazol 200 mg/d | placebo | Stade de la maladie: II | | Strandness, 2002 | cilostazol 50 or 100 mg twice daily | placebo | AOMI stade II. | | Dawson (cilostazol), 2000 | Cilostazol 200 mg/d | placebo | Stade de la maladie: II en situation chronique. | | Elam, 1998 | cilostazol 100 mg twice daily | placebo | | | Otsuka 21-95-201, | cilostazol 100 or 150 mg twice daily | | |
| |
| Ginko biloba | peripheral vascular diseases, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Revascularization | no data | | All cause death | 0.80 [0.02 41.12] | p=1.00 | 0 | 79 | 1 | Bauer, | | Treatment related complication | 0.39 [0.06 2.70] | p=1.00 | 0 | 190 | 2 | Bauer, Peters, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bauer, 1984 | ginko biloba 40 mg three times daily | placebo | AOMI stade IIb | | Peters, 1998 | ginko biloba EGb 761 three times daily | placebo | AOMI stade IIb |
| |
| Naftidrofuryl | peripheral vascular diseases, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputation | no data | | All cause death | 0.67 [0.04 11.49] | p=1.00 | 0 | 40 | 1 | Meehan, | | Treatment related complication | 0.68 [0.01 36.35] | p=1.00 | 0 | 37 | 1 | Meehan, |
| Trial | Studied treatment | Control | Patients |
|---|
| Meehan, 1982 | Naftidrofuryl (Nafronyl): par voie IV ( 200 mg*2/ jour pendant 2 heures dans 500 ml de sérum salé isotonique) et par voie orale ( 200mg*3/ jour)+ repos au lit + réchauffement pendant 7 jours | Repos au lit + réchauffement | AOMI stade III |
| |
| Naftidrofuryl | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputation | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.56 [0.07 4.40] | p=1.00 | 0 | 450 | 2 | NIQOL germany, NCIS, | | stroke (fatal and non fatal) | 1.03 [0.02 52.67] | p=1.00 | 0 | 181 | 1 | NCIS, | | Revascularization | no data | | All cause death | 0.33 [0.09 1.18] | p=1.00 | 0 | 1033 | 5 | NIQOL germany, Clyne, NIQOL belgium, NCIS, D'Hooge D, | | Treatment related complication | 0.85 [0.43 1.68] | p=1.00 | 0 | 401 | 2 | NIQOL belgium, NCIS, |
| Trial | Studied treatment | Control | Patients |
|---|
| NIQOL germany, 1999 | Naftidrofuryl 600 mg/d | placebo | Stade de la maladie: II, durée (années): 2.41+/-2.67 en moyenne. | | Clyne, 1980 | Naftidrofuryl 100 mg/d | placebo | AOMI stade II | | NIQOL belgium, 2001 | Naftidrofuryl 200mg three times daily | placebo | Stade de la maladie :II pendant 4.1 ans en moyenne | | NCIS, 2001 | naftidrofuryl 200 mg three times daily | placebo | Stade de la maladie: II pendant 5.25 ans en moyenne | | Testart, 1994 | 2 daily infusions of 400 mg of naftidrofuryl for 8 days | placebo | AOMI stade III ou IV | | DHooge D, 2001 | - effet de naftidrofuryl sur la qualité de vie de patients souffrant de claudication intermittente stable :
3x200mg pdt 6 mois | - placebo pdt 6 mois | - 235 patients
- âge moyen 66,5 ans
- 66,4% dhommes |
| |
| Naftidrofuryl | | vs prostacyclin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputation | no data | | All cause death | no data | | Treatment related complication | 0.08 [0.00 1.73] | p=1.00 | 0 | 29 | 1 | Negus, |
| Trial | Studied treatment | Control | Patients |
|---|
| Negus, 1987 | Naftidrofuryl 0.02 mg/kg/min, intra-arterial, 3 days | intra-arterial prostacyclin 8 ng/kg/min, 3 days | Stade de la maladie: III: 55.2%; IV: 44.8%Durée de la douleur (semaines): groupe contrôle: 30 +/-54.2 groupe ttt: 19.7 +/- 44.6 |
| |
| Pentoxifylline | peripheral vascular diseases, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.84 [0.19 3.70] | p=1.00 | 0 | 342 | 4 | APIC, Donaldson, Porter, Belcaro, | | stroke (fatal and non fatal) | 0.49 [0.04 5.92] | p=1.00 | 0 | 202 | 2 | APIC, Porter, | | Revascularization | no data | | All cause death | 0.87 [0.16 4.83] | p=1.00 | 0 | 605 | 3 | Dawson (pentoxifylline), APIC, Belcaro, | | Treatment related complication | 1.00 [0.02 52.10] | p=1.00 | 0 | 60 | 1 | Belcaro, |
| Trial | Studied treatment | Control | Patients |
|---|
| Dawson (pentoxifylline), 2000 | Pentoxifylline 1200 mg/d | placebo | Stade de la maladie: II en situation chronique. | | APIC, 1989 | Pentoxifylline 800 mg/d | placebo | Stade de la maladie : II, avec durée des symptômes de 10 mois en moyenne. | | Donaldson, 1984 | Oxpentifylline 600 mg/d | placebo | AOMI stade II | | Porter, 1982 | Pentoxifylline between 600 mg/d and 1200 mg/d | placebo | Stade de lartériopathie: II, avec durée des symptomes de 2.9 ans en moyenne. | | Belcaro, 2002 | Pentoxifylline 1600 mg/d | placebo | Stade de la maladie: II avec durée de la claudication de: 3+/- 2 mois en moyenne. |
| |
